Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-10-05 4:36 pm Purchase | 2023-10-03 | 13D | Madrigal Pharmaceuticals, Inc. MDGL | BAKER BROS. ADVISORS LP | 2,015,760 9.990% | 470,647 (+30.46%) | Filing History |
| 2023-08-17 5:12 pm Sale | 2023-08-15 | 13D | Neoleukin Therapeutics, Inc. NLTX | BAKER BROS. ADVISORS LP | 473,605 19.990% | -28,549 (-5.69%) | Filing History |
| 2023-08-10 4:42 pm Sale | 2023-07-31 | 13G | Mereo BioPharma Group plc MREO | BAKER BROS. ADVISORS LP | 14,604,391 2.200% | -54,754,968 (-78.94%) | Filing History |
| 2023-08-10 4:39 pm Sale | 2023-07-31 | 13G | Verastem, Inc. VSTM | BAKER BROS. ADVISORS LP | 0 0.000% | -1,345,192 (Position Closed) | Filing History |
| 2023-08-08 5:16 pm Unchanged | 2023-08-07 | 13D | Madrigal Pharmaceuticals, Inc. MDGL | BAKER BROS. ADVISORS LP | 1,545,113 8.400% | 0 (Unchanged) | Filing History |
| 2023-07-19 5:28 pm Purchase | 2023-07-17 | 13D | Neoleukin Therapeutics, Inc. NLTX | BAKER BROS. ADVISORS LP | 502,154 19.990% | 290,663 (+137.43%) | Filing History |
| 2023-06-28 5:01 pm Purchase | 2023-06-22 | 13D | IGM Biosciences, Inc. IGMS | BAKER BROS. ADVISORS LP | 3,277,567 9.990% | 107,673 (+3.40%) | Filing History |
| 2023-06-16 7:18 pm Unchanged | 2023-06-15 | 13D | Madrigal Pharmaceuticals, Inc. MDGL | BAKER BROS. ADVISORS LP | 1,545,113 8.400% | 0 (Unchanged) | Filing History |
| 2023-06-12 4:37 pm Purchase | 2023-05-31 | 13G | Verastem, Inc. VSTM | BAKER BROS. ADVISORS LP | 1,345,192 8.000% | 1,345,192 (New Position) | Filing History |
| 2023-06-02 4:06 pm Purchase | 2023-05-25 | 13D | TScan Therapeutics, Inc. TCRX | BAKER BROS. ADVISORS LP | 2,793,938 6.500% | 9,146 (+0.33%) | Filing History |
| 2023-05-24 5:11 pm Purchase | 2023-05-23 | 13D | ACADIA Pharmaceuticals Inc. ACAD | BAKER BROS. ADVISORS LP | 43,227,599 26.500% | 920,810 (+2.18%) | Filing History |
| 2023-05-24 4:31 pm Purchase | 2023-05-18 | 13D | Prelude Therapeutics Incorporated PRLD | BAKER BROS. ADVISORS LP | 10,219,080 19.500% | 92,663 (+0.92%) | Filing History |
| 2023-05-05 4:33 pm Sale | 2023-05-03 | 13D | BeiGene, Ltd. ONC | BAKER BROS. ADVISORS LP | 152,978,037 13.000% | -1,337,453 (-0.87%) | Filing History |
| 2023-05-05 4:24 pm Purchase | 2023-05-05 | 13D | Bellicum Pharmaceuticals, Inc. BLCM | BAKER BROS. ADVISORS LP | 2,197,919 19.990% | 2,197,919 (New Position) | Filing History |
| 2023-05-03 4:15 pm Purchase | 2023-05-01 | 13D | Seagen Inc. SGEN | BAKER BROS. ADVISORS LP | 45,074,469 24.000% | 45,074,469 (New Position) | Filing History |
| 2023-03-15 4:09 pm Purchase | 2023-03-13 | 13D | Incyte Corporation INCY | BAKER BROS. ADVISORS LP | 36,641,462 16.400% | 7,108 (+0.02%) | Filing History |
| 2023-03-13 4:30 pm Purchase | 2023-03-12 | 13D | Seagen Inc. SGEN | BAKER BROS. ADVISORS LP | 47,233,651 25.300% | 10,043 (+0.02%) | Filing History |
| 2023-03-10 4:55 pm Purchase | 2023-03-10 | 13D | Talis Biomedical Corporation TLIS | BAKER BROS. ADVISORS LP | 2,505,086 66.200% | 4,750 (+0.19%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | BAKER BROS. ADVISORS LP | 2,368,378 5.100% | 2,368,378 (New Position) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Aravive, Inc. ARAV | BAKER BROS. ADVISORS LP | 4,586,404 7.500% | 4,586,404 (New Position) | Filing History |